iCMLf International Chronic Myeloid Leukemia Foundation

ESH EUROPEAN SCHOOL OF HAEMATOLOGY

25th Annual John Goldman Conference
CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY
October 6-8, 2023 – Mandelieu-La Napoule, France

Chairs: J. Cortes, T.P. Hughes, D.S. Krause
Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, V. Helgason, S. T. Ong, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, F-X. Mahon, D. Perrotti, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

Friday, October 6, 2023

08:00-08:10	**Welcome to Mandelieu**	Jorge Cortes (Augusta)
08:10-08:20	**iCMLf - A REVIEW**	Tim P. Hughes (Adelaide)

SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2023 *(12' + 3' discussion)*
Chairs: Ilaria S. Pagani (Adelaide), Tim Brümmendorf (Aachen)

08:20-08:35	The SSRI paroxetine an inhibitor of the serotonin transporter SERT targets both c-Myc-dependent and inflammatory CML LSC	Athina Varnava (Glasgow)
08:35-08:50	Nilotinib vs. nilotinib plus peg-Interferon alpha induction and nilotinib or peg-Interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. The TIGER trial	Andreas Hochhaus (Jena)
08:50-09:05	Leukaemia exposure reduces phagocytosis and efferocytosis in Philadelphia negative bone marrow-derived macrophages	Martha M. Zarou (Glasgow)
09:05-09:20	Clonal hematopoiesis mutants detected at the time of stopping therapy in deep molecular response are significantly associated with achievement of treatment-free remission (TFR)	Susan Branford (Adelaide)
09:20-09:35	Distinct and targetable role of calcium and calcium sensing receptor in leukaemia	Raquel S. Pereira (Frankfurt)
09:35-09:50	Frontline asciminib combination in chronic phase chronic myeloid leukemia patients. The FASCINATION trial	Andreas Hochhaus (Jena)
09:50-10:05	Excellent molecular responses and tolerance observed with frontline asciminib treatment for CP-CML: results from the ALLG CML13 ASCEND-CML study	Tim P. Hughes (Adelaide)

10:05-10:20 Coffee Break

TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE (1) *(15' + 5' discussion)*
Chair: Mhairi Copland (Glasgow)

10:20-10:40	Autophagy networks and cancer pathogenesis	Ivan Dikic (Frankfurt)
10:40-10:45	*Discussion*	

SCIENTIFIC SESSION 2: Stem cells
Chair: Daniela Krause (Frankfurt)

10:45-11:00	**Keynote Presentation:** The curious case of the leukemic stem cell: why is it so elusive?	Ravi Bhatia (Birmingham)
11:00-11:05	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
11:05-11:20	LSC molecular phenotypes, lineage potentialities and diversity are influenced by human cytokine expression in PDX models of CML	Mary Scott (Glasgow)
11:20 -11:35	SETD2/H3K36mE3 deficiency hinders proper dna damage repair and enhances clonogenic potential of chronic myeloid leukemia (CML) progenitors	Manuela Mancini (Bologna)
11:35-11:50	Multiomic single-cell characterization of the CD14-CD34+ stem and progenitor cell compartment in chronic myeloid leukemia	Malin S. Nilsson (Gothenburg)
11:50-12:05	Clonal medicine targeting DNA damage response eradicates myeloid leukemia	Tomasz Skorski (Philadelphia)
12:05-12:20	**JANET ROWLEY PRIZE PRESENTATION** **Presenter:** Michael Deininger (Milwaukee) **Awardee 2023:** Jerry Radich (Seattle)	

JANET ROWLEY PRIZE: SPECIAL LECTURE (2)
Chair: Michael Deininger (Milwaukee)

12:20-12:40	CML is still important and relevant	Jerry Radich (Seattle)
12:40-12:45	*Discussion*	

12:45-14:40 Lunch and Poster Viewing

13:30-14:30 **SATELLITE SYMPOSIUM**
Living with CML: How optimizing tolerability can lead to better patient outcomes
Chair: Andreas Hochhaus (Jena)
Speakers: Andreas Hochhaus (Jena), Daniela Žáčková (Brno), Fausto Castagnetti (Bologna)

This symposium is organized and sponsored by Novartis

This session is intended for non-US healthcare professionals

SPECIAL LECTURE (3):
Chair: Dennis Kim (Toronto)

14:40-15:00	Germline predisposition to hematopoietic malignancies	Lucy Godley (Chicago)
15:00-15:05	*Discussion*	

SCIENTIFIC SESSION 3: Mechanisms of resistance and new targets
Chair: Helong Zhao (Milwaukee)

15:05-15:20	**Keynote Presentation:** Resistance to TKI: mutations and beyond	Simona Soverini (Bologna)
15:20-15:25	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
15:25-15:40	The role of G0/G1 switch gene 2 (G0S2) in lipid metabolism, differentiation, and drug resistance in chronic myeloid leukemia (CML)	Anna Eiring (El Paso)
15:40-15:55	Overcoming TKI-resistant CML utilizing a novel PROTAC-based BCR::ABL1 degrader	Milad Rouhimoghadam (Milwaukee)
15:55-16:10	Characterization of bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option	Hong Qian (Stockholm)
16:10-16:40	***Coffee Break***	

MICHELE BACCARANI SPECIAL SYMPOSIUM *(12' + 5' discussion)*
Chair: Shinya Kimura (Saga)

16:40-16:50	Introductory overview – concepts and challenges	
16:50-17:07	TP53 mutations in myeloid malignancies	Steffen Boettcher (Zurich)
17:07-17:24	The BCL2 family in myeloid malignancies	Caroline Heckman (Helsinki)
17:24-17:41	CD47 Targeting in myeloid malignancies	Ravindra Majeti (Stanford)
17:41-17:58	Clonal hematopoiesis	R. Coleman Lindsley (Boston)
17:58-18:15	Defective neutrophil clearance causes pathogenic microenvironmental interactions in MPN	Simon Méndez-Ferrer (Cambridge)
18:15-18:45	General Discussion	

18:50-20:00 **Poster Viewing and Welcome Get-Together**
Mentored Poster Walk 1
- *Biology Poster Walk Leaders: Vignir Helgason (Glasgow), Mirle Schemionek-Reinders (Aachen)*
- *Clinical Poster Walk Leaders: Mhairi Copland (Glasgow), Dragana Milojkovic (London)*

18:50-19:50	**CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**	
	1. The pharmaceutics of cell therapy manufacturing	Halvard Boenig (Frankfurt)
	2. Third line approach	Delphine Rea (Paris)
	3. Clonal hematopoiesis of indeterminate potential – basic aspects and clinical implications	Steffen Boettcher (Zurich)

Saturday, October 7, 2023

WORKSHOP FOR NON-CLINICAL SCIENTISTS #1: IMAGING
Chairs: Ravi Bhatia (Birmingham, USA), Daniela Krause (Frankfurt)

08:00-08:05	Introduction	
08:05-08:30	Anatomical control of hematopoiesis	Daniel Lucas (Cincinnati) (*virtual)*
08:30-08:55	Healthy and malignant haematopoietic stem cells in the bone marrow microenvironment	Cristina Lo Celso (London)
08:55-09:05	*Discussion*	
09:05-09:30	3D quantitative microscopy of hematopoietic stem cell interactions with the bone marrow microenvironment	César Nombela-Arrieta (Zurich)
09:30-09:40	*Discussion*	
09:40-09:50	Conclusion	

09:00-10:00	**CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**	
	1. Targeting BCL2 family members in myeloid leukemia	Caroline Heckman (Helsinki)
	2. Identifying and testing people at risk for inherited susceptibility to hematopoietic malignancies	Lucy Godley (Chicago)
	3. General aspects of optimal dosing strategies for TKIs	Jorge Cortes (Augusta)

09:50-10:15 Coffee Break

SCIENTIFIC SESSION 4: Biomarkers
Chair: Vivian Oehler (Seattle)

10:15-10:30	**Keynote Presentation:** Hidden signatures: harnessing the full power of biomarkers in chronic myeloid leukaemia	Sin Tiong Ong (Singapore)
10:30-10:35	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
10:35-10:50	The presence of somatic mutations prior to treatment-free remission (TFR) attempt is not associated with TFR failure following tyrosine kinase inhibitor (TKI)	Dennis Kim (Toronto)

	discontinuation in chronic myeloid leukemia patients	
10:50-11:05	Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure: a report from the RESIDIAG study	Ivan Sloma (Creteil)
11:05-11:20	BCL-XL a novel biomarker for treatment failure and treatment-free remission in chronic myeloid leukaemia	Claire Lucas (Chester)
11:20-11:35	KIR3DL1-HLA-Bw status predict favourable achievement of treatment free remission in CML: results from the POKSTIC trial, a multicentre retrospective observational study	Hiroshi Ureshino (Hiroshima)
11:35-11:50	Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response	Rebecca Warfvinge (Lund)
11:50-12:00	**ESH SCHOLARSHIP FUND AWARD CEREMONY** **LEUKAEMIA UK INTERNATIONAL SCHOLARSHIP** **Chair:** Nick Cross (Southampton)	

12:00-13:55 Lunch and Poster Viewing

12:45-13:45 **SATELLITE SYMPOSIUM**
How can emerging data further optimise treatment of TKI-resistant CML?
Chair: Delphine Réa (Paris)
Speakers: Thomas Lion (Vienna), Gianantonio Rosti (Meldola), Delphine Réa (Paris)

This symposium is organized and sponsored by Incyte

SPECIAL LECTURE (4):
Chair: Franck Nicolini (Lyon)

13:55-14:15	Novel developments in HSC transplant, treatment of GVHD	Halvard Boenig (Frankfurt)
14:15-14:20	*Discussion*	

DEBATE: Genomic screening is essential prior to frontline therapy?
Chair: Pierre Laneuville (Montreal)

14:20-14:25	Introduction	Pierre Laneuville (Montreal)

Audience votes

14:25-14:35	Not yet	Jane Apperley (London)
14:35-14:45	Pro	Giuseppe Saglio (Turin)
14:45-15:00	*Discussion*	

Audience votes again

SCIENTIFIC SESSION 5: Treatment-free remission
Chair: Susanne Saussele (Mannheim)

15:00-15:20	**Keynote Presentation:** TFR: How do we move forward?	Massimo Breccia (Rome) *(virtual)*
	Selected Abstracts: *(12' + 3' discussion)*	
15:20-15:35	The European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission	Francois-Xavier Mahon (Bordeaux)
15:35-15:50	Treatment free remissions (TFR) in children with chronic myeloid leukemia (CML) - A prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort	Nirmalya Roy Moulik (Mumbai)
15:50-16:05	A successful treatment-free remission is achievable also by CML patients lacking optimal requirements	Massimiliano Bonifacio (Verona)
16:05-16:20	Tyrosine kinase inhibitor-free remission after salvage therapy for resistance, warning or lack of deep molecular response in chronic myeloid leukemia	Delphine Rea (Paris)
16:20-16:50	***Coffee Break***	
16:50-17:05	**JOHN GOLDMAN PRIZE PRESENTATION** **Presenter:** François-Xavier Mahon (Bordeaux) **Awardee 2023:** Francois Guilhot (Poitiers)	

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (5)
Chair: François-Xavier Mahon (Bordeaux)

17:05-17:25	From IRIS to SPIRIT toward treatment discontinuation for CML patients	François Guilhot (Poitiers)
17:25-17:30	*Discussion*	

SCIENTIFIC SESSION 6: Treatment-free remission: why and why not
Chair: Ehab Atallah (Milwaukee)

17:30-17:45	**Keynote Presentation:** Are current recommendations enough or too much?	Dragana Milojkovic (London)
17:45-17:50	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
17:50-18:05	Sensitive measurement of residual disease in granulocytes and T cells strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy	Ilaria S. Pagani (Adelaide)
18:05-18:20	Why are not all eligible CML patients willing to attempt TKI discontinuation?	Daniela Zackova (Brno)

18:20-18:35	Myelofibrosis at diagnosis could prevent successful treatment-free remission in CML patients	Henrike Jacobi (Aachen)

18:45-19:45 ***Mentored Poster Walk 2***

- *Biology Poster Walk Leaders: Vignir Helgason (Glasgow), Mirle Schemionek-Reinders (Aachen)*
- *Clinical Poster Walk Leaders: Mhairi Copland (Glasgow), Dragana Milojkovic (London)*

20:30-23:00 *Faculty Dinner*

Sunday, October 8, 2023

07:00-08:00 JOHN GOLDMAN CML FUN RUN (Pre-registration required)

WORKSHOP FOR NON-CLINICAL SCIENTISTS #2: SINGLE CELL ANALYSIS
Chairs: Mhairi Copland (Glasgow), Sin Tiong Ong (Singapore)

09:00-09:05	Introduction	
09:05-09:30	Single cell technologies to explore the role of ageing in the hematopoietic system	Kristina Kirschner (Glasgow)
09:30-09:40	*Discussion*	
09:40-10:05	Mass cytometry for assessment of response to therapy in leukemia	Bjorn Tore Gjertsen (Bergen)
10:05-10:15	*Discussion*	
10:15-10:40	New insights into human diseases using single cell atlases	Shyam Prabhakar (Singapore)
10:40-10:50	*Discussion*	
10:50-11:00	Conclusion	

SCIENTIFIC SESSION 7: Long-term outcomes and safety
Chair: Michael Mauro (New York)

09:45-10:00	**Keynote Presentation:** CML: Have we reached the peak?	Carlo Gambacorti-Passerini (Monza)
10:00-10:05	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
10:05-10:20	CML-Registry (CML VI): achievement of ELN treatment milestones is predictive for deep molecular response (DMR) in real-world setting	Katharina Kohlbrenner (Mannheim)
10:20-10:35	The effect of body mass Index on the safety of bosutinib in patients with chronic myeloid leukemia: a post hoc pooled data analysis	Susanne Isfort (Aachen)

10:35-11:05 ***Coffee Break***

SPECIAL LECTURE (6):
Chair: Sin Tiong Ong (Singapore)

11:05-11:25	Identification and exploitation of the metabolic reprogramming suffered by CML cells that acquire Tyrosine Kinase Inhibitor (TKI) resistance	Marta Cascante (Barcelona)
11:25-11:30	*Discussion*	
11:30-11:45	**iCMLf PRIZE PRESENTATION:** **Presenter:** Giuseppe Saglio (Turin) **Awardees 2023:** Iryna Dyagil (Kyiv), Kostyantyn Kotlyarchuk (Lviv)	

iCMLf PRIZE: SPECIAL LECTURE (7)
Chair: Giuseppe Saglio (Turin)

11:45-12:05	Hematology service for CML patients in Ukraine: challenges and successes	Iryna Dyagil (Kyiv) Kostyantyn Kotlyarchuk (Lviv)
12:05-12:10	*Discussion*	

SCIENTIFIC SESSION 8: Predictive models and markers
Chair: Tim Hughes (Adelaide)

12:10-12:25	**<u>Keynote Presentation</u>:** How should we interpret concussions of TKI-stopping studies?	Robert Peter Gale (London)
12:25-12:30	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
12:30-12:45	A predictive scoring system for therapy failure of tyrosine-kinase inhibitors in patients with chronic myeloid leukemia	Xiaoshuai Zhang (Beijing)
12:45-13:00	Somatic mutations in cancer-related genes were observed more frequently in AYA CML patients compared to elderly at diagnosis, whereas the frequency was markedly higher in elderly patients during TKI treatment	Jitka Krizkova (Prague)

13:00-13:05 Closing Remarks

MEETING CLOSURE